Literature DB >> 15656792

Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.

Benoit Bilanges1, David Stokoe.   

Abstract

RNAi (RNA interference) and ASO (antisense oligonucleotide) technologies are the most commonly used approaches for silencing gene expression. However, the specificity of such powerful tools is an important factor to correctly interpret the biological consequences of gene silencing. In the present study, we examined the effects of acute loss of Ser/Thr kinase PDK1 (3-phosphoinositide-dependent kinase 1) expression using ASO and RNAi, and compared, for the first time, these two techniques using Affymetrix microarrays. We show that both ASO- and siRNA (small interfering RNA)-mediated knock-down of PDK1 expression strongly inhibited cell proliferation, although by different mechanisms, thereby questioning the specificity of these reagents. Using microarray analysis, we characterized the specificity of the ASO- and siRNA-mediated gene silencing of PDK1 by examining expression profiles 48 and 72 h following oligonucleotide transfection. At 48 h, a PDK1-dependent pattern of gene alterations was detectable, despite a large number of non-specific changes due to transfection of control nucleic acids. These non-specific alterations became more apparent at the 72 h time point, and obscured any PDK1-specific pattern. This study underscores the importance of defining appropriate control ASOs and siRNAs, using multiple oligonucleotides for each target and preferably short time points following transfection to avoid misinterpretation of the phenotype observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15656792      PMCID: PMC1138965          DOI: 10.1042/BJ20041956

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  66 in total

1.  Confirming specificity of RNAi in mammalian cells.

Authors:  Patrice Lassus; Joe Rodriguez; Yuri Lazebnik
Journal:  Sci STKE       Date:  2002-08-27

Review 2.  Gene silencing in mammals by small interfering RNAs.

Authors:  Michael T McManus; Phillip A Sharp
Journal:  Nat Rev Genet       Date:  2002-10       Impact factor: 53.242

3.  Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells.

Authors:  Makoto Miyagishi; Mariko Hayashi; Kazunari Taira
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2003-02

4.  A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3 kinase signals that regulate diapause in Caenorhabditis elegans.

Authors:  S Paradis; M Ailion; A Toker; J H Thomas; G Ruvkun
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

5.  A phosphoserine/threonine-binding pocket in AGC kinases and PDK1 mediates activation by hydrophobic motif phosphorylation.

Authors:  Morten Frödin; Torben L Antal; Bettina A Dümmler; Claus J Jensen; Maria Deak; Steen Gammeltoft; Ricardo M Biondi
Journal:  EMBO J       Date:  2002-10-15       Impact factor: 11.598

6.  Functional counterparts of mammalian protein kinases PDK1 and SGK in budding yeast.

Authors:  A Casamayor; P D Torrance; T Kobayashi; J Thorner; D R Alessi
Journal:  Curr Biol       Date:  1999-02-25       Impact factor: 10.834

7.  Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis.

Authors:  Anna Astriab Fisher; Dongjiu Ye; Dimitri S Sergueev; Michael H Fisher; Barbara Ramsay Shaw; Rudolph L Juliano
Journal:  J Biol Chem       Date:  2002-04-10       Impact factor: 5.157

8.  Essential role of PDK1 in regulating cell size and development in mice.

Authors:  Margaret A Lawlor; Alfonso Mora; Peter R Ashby; Michayla R Williams; Victoria Murray-Tait; Lorraine Malone; Alan R Prescott; John M Lucocq; Dario R Alessi
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

9.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.

Authors:  Michael T Hemann; Jordan S Fridman; Jack T Zilfou; Eva Hernando; Patrick J Paddison; Carlos Cordon-Cardo; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

10.  Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis.

Authors:  Timothy A Vickers; Seongjoon Koo; C Frank Bennett; Stanley T Crooke; Nicholas M Dean; Brenda F Baker
Journal:  J Biol Chem       Date:  2002-12-23       Impact factor: 5.157

View more
  17 in total

1.  Use of recombinant calpain-2 siRNA adenovirus to assess calpain-2 modulation of lung endothelial cell migration and proliferation.

Authors:  Kai Qiu; Yunchao Su; Edward R Block
Journal:  Mol Cell Biochem       Date:  2006-05-30       Impact factor: 3.396

Review 2.  Lentiviral vector-mediated RNA silencing in the central nervous system.

Authors:  Thomas H Hutson; Edmund Foster; Lawrence D F Moon; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther Methods       Date:  2013-11-01       Impact factor: 2.396

3.  Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.

Authors:  Kumiko Nagashima; Stuart D Shumway; Sriram Sathyanarayanan; Albert H Chen; Brian Dolinski; Youyuan Xu; Heike Keilhack; Thi Nguyen; Maciej Wiznerowicz; Lixia Li; Bart A Lutterbach; An Chi; Cloud Paweletz; Timothy Allison; Youwei Yan; Sanjeev K Munshi; Anke Klippel; Manfred Kraus; Ekaterina V Bobkova; Sujal Deshmukh; Zangwei Xu; Uwe Mueller; Alexander A Szewczak; Bo-Sheng Pan; Victoria Richon; Roy Pollock; Peter Blume-Jensen; Alan Northrup; Jannik N Andersen
Journal:  J Biol Chem       Date:  2010-11-30       Impact factor: 5.157

4.  Puromycin-resistant lentiviral control shRNA vector, pLKO.1 induces unexpected cellular differentiation of P19 embryonic stem cells.

Authors:  Jyotshna Kanungo
Journal:  Biochem Biophys Res Commun       Date:  2017-03-16       Impact factor: 3.575

5.  Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules.

Authors:  Jonathan E Phipps; Daniel P Kestler; James S Foster; Stephen J Kennel; Robert Donnell; Deborah T Weiss; Alan Solomon; Jonathan S Wall
Journal:  Exp Hematol       Date:  2010-07-14       Impact factor: 3.084

6.  MicroRNA-like off-target transcript regulation by siRNAs is species specific.

Authors:  Julja Burchard; Aimee L Jackson; Vladislav Malkov; Rachel H V Needham; Yejun Tan; Steven R Bartz; Hongyue Dai; Alan B Sachs; Peter S Linsley
Journal:  RNA       Date:  2009-02       Impact factor: 4.942

7.  3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.

Authors:  Matthew Maurer; Tao Su; Lao H Saal; Susan Koujak; Benjamin D Hopkins; Christina R Barkley; Jiaping Wu; Subhadra Nandula; Bhaskar Dutta; Yuli Xie; Y Rebecca Chin; Da-In Kim; Jennifer S Ferris; Sofia K Gruvberger-Saal; Mervi Laakso; Xiaomei Wang; Lorenzo Memeo; Albert Rojtman; Tulio Matos; Jennifer S Yu; Carlos Cordon-Cardo; Jorma Isola; Mary Beth Terry; Alex Toker; Gordon B Mills; Jean J Zhao; Vundavalli V V S Murty; Hanina Hibshoosh; Ramon Parsons
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

8.  Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.

Authors:  Sophie Iochmann; Claire Bléchet; Valérie Chabot; Annabelle Saulnier; Aniça Amini; Guillaume Gaud; Yves Gruel; Pascale Reverdiau
Journal:  Clin Exp Metastasis       Date:  2009-03-07       Impact factor: 5.150

9.  A status report on RNAi therapeutics.

Authors:  Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore
Journal:  Silence       Date:  2010-07-08

10.  miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells.

Authors:  Abdelfattah El Ouaamari; Nadine Baroukh; Geert A Martens; Patricia Lebrun; Daniel Pipeleers; Emmanuel van Obberghen
Journal:  Diabetes       Date:  2008-06-30       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.